🦋
Non-Surgical · Minimally Invasive · In-Office
District Endocrine now offers ultrasound-guided microwave ablation (MWA) for benign thyroid nodules — a safe, effective alternative to surgery for patients with symptomatic or cosmetically bothersome thyroid nodules.
What Is Thyroid Microwave Ablation?
Thyroid microwave ablation (MWA) is a minimally invasive, ultrasound-guided procedure that uses microwave energy delivered through a thin needle (antenna) to heat and destroy thyroid nodule tissue from the inside — causing the nodule to shrink significantly over the following weeks and months. The surrounding healthy thyroid tissue is preserved, and thyroid function remains intact in the vast majority of patients.
MWA has rapidly emerged as one of the most effective thermal ablation modalities for benign thyroid nodules. Major professional societies including the American Thyroid Association (ATA), European Thyroid Association (ETA), American Association of Endocrine Surgeons (AAES), and Society of Interventional Radiology (SIR) now formally endorse thermal ablation for appropriately selected patients. A 2024 international expert consensus published in Radiology also supports ultrasound-guided thermal ablation for selected cases of low-risk papillary thyroid cancer (T1N0M0).
How Microwave Ablation Works
Microwave Energy
Microwave ablation uses electromagnetic energy in the microwave frequency range (typically 915 MHz or 2.45 GHz) to agitate water molecules within the nodule tissue, generating frictional heat that causes coagulative necrosis — destroying the nodule from within.
Ultrasound Guidance
Real-time ultrasound imaging is used throughout the procedure to precisely position the microwave antenna within the nodule and monitor the ablation zone in real time, ensuring complete nodule treatment while protecting surrounding structures including the recurrent laryngeal nerve, trachea, and carotid artery.
Progressive Shrinkage
Following ablation, the treated nodule tissue is gradually resorbed by the body. Studies show average volume reduction ratios (VRR) of 70–90% at 12 months, with continued shrinkage beyond 12 months. Symptoms improve proportionally as the nodule shrinks.
Indications — Who Is a Candidate?
Based on the ATA 2023 Consensus Statement, the ETA 2020 Clinical Practice Guidelines, and published clinical evidence, the following patients may be candidates for thyroid microwave ablation:
- ✔Benign thyroid nodules confirmed on biopsy (FNA) that are symptomatic — causing neck pressure, difficulty swallowing, choking sensation, or voice changes
- ✔Cosmetically bothersome nodules — visible neck enlargement causing patient distress
- ✔Autonomously functioning thyroid nodules (AFTN) causing subclinical or overt hyperthyroidism — MWA has demonstrated excellent results in reducing nodule volume and normalizing thyroid function
- ✔Patients who decline or cannot undergo surgery — including those with high surgical risk due to comorbidities, anticoagulation, or prior neck surgery
- ✔Selected low-risk papillary thyroid cancers (T1N0M0) — per 2024 international expert consensus in Radiology, as an alternative for patients declining active surveillance and surgery
- ✔Multinodular goiter — MWA can treat multiple nodules in a single session, with a 2025 study confirming effectiveness for both solitary nodules and multinodular goiters
What to Expect — The Procedure
Before the Procedure
A comprehensive evaluation including thyroid ultrasound, confirmed benign FNA biopsy, thyroid function tests, and review of medications (blood thinners may need to be paused). Nodule size, location, and proximity to critical structures are assessed before the procedure.
Day of Procedure
Performed in-office under local anesthesia and ultrasound guidance. A thin microwave antenna is inserted through the skin into the nodule. The "moving shot technique" is used to systematically ablate the nodule while protecting surrounding structures. Hydrodissection with saline creates a safety margin around critical structures including the recurrent laryngeal nerve. Duration: typically 15–45 minutes depending on nodule size.
After the Procedure
Most patients return to normal activities the same day or the next day. Ultrasound follow-up is performed at 1, 6, and 12 months to monitor nodule volume reduction. The treated nodule gradually shrinks as the body resorbs the ablated tissue. Thyroid function is monitored via blood tests at follow-up visits.
Clinical Evidence & Outcomes
Microwave ablation is supported by a growing body of high-quality clinical evidence:
- 📄Volume Reduction: Multiple studies report mean volume reduction ratios (VRR) of 70–90% at 12 months for benign thyroid nodules, with continued shrinkage at 24 months. A 2025 study (Frontiers in Oncology) confirmed significant volume reduction in both solitary nodules and multinodular goiters.
- 📄Safety Profile: MWA has a well-established safety record. Serious complications are rare. The most common minor side effects are transient neck pain or discomfort during the procedure. Thyroid function is preserved in the vast majority of patients.
- 📄Autonomously Functioning Nodules: A 2025 review in the European Medical Journal confirmed MWA as a safe and effective treatment for autonomously functioning thyroid nodules (AFTNs), with normalization of thyroid function in most cases.
- 📄Papillary Thyroid Cancer (T1N0M0): The 2024 International Expert Consensus published in Radiology endorses thermal ablation including MWA as a first-line treatment for T1aN0M0 papillary thyroid carcinoma and as an alternative for T1bN0M0 disease in selected patients who decline surgery.
- 📄2024 Chinese Guidelines: The current international guidelines and published clinical evidence
Advantages Over Surgery
No General Anesthesia
Performed under local anesthesia only. No risks associated with general anesthesia, intubation, or sedation.
No Surgical Scar
A single needle puncture is used — no neck incision, no visible scar.
Thyroid Function Preserved
Only the target nodule is treated. Healthy thyroid tissue is preserved — most patients do not require thyroid hormone replacement after MWA.
Fast Recovery
Most patients return to work the same day or the next day. No hospital admission required.
Repeatable
If needed, the procedure can be repeated. Multiple nodules can be treated in a single session.
Low Complication Rate
No risk of surgical complications such as hypoparathyroidism or permanent recurrent laryngeal nerve injury — risks that are inherent to thyroidectomy.
🔑 Key Takeaways
- Thyroid microwave ablation (MWA) is a non-surgical, minimally invasive treatment to shrink benign thyroid nodules and selected low-risk thyroid cancers.
- Endorsed by the American Thyroid Association (ATA) 2023 Consensus Statement, with joint endorsement by AAES, AAO-HNS, AHNS, and SIR, and the European Thyroid Association (ETA) 2020 Clinical Practice Guidelines.
- Average nodule volume reduction of 70–90% at 12 months across multiple published studies.
- Performed in-office under local anesthesia and real-time ultrasound guidance — no hospital admission, no general anesthesia, no surgical scar.
- Thyroid function is preserved in the vast majority of patients — no need for lifelong thyroid hormone replacement.
- Effective for both solid and mixed solid-cystic nodules, autonomously functioning nodules, and multinodular goiters.
- Safe for selected low-risk papillary thyroid cancers (T1N0M0) in patients who decline surgery.
- Most patients return to normal activities the same day or next day.
- Offered at District Endocrine — Northern Virginia.
Your Provider
Thyroid Microwave Ablation at District Endocrine
Medical Disclaimer: This page is for informational purposes only and does not constitute individualized medical advice. Please consult with a qualified healthcare provider to determine if this procedure or test is appropriate for your specific situation.